Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SI | P14410 | 1/20 | 0.30 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.30 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL124942 | 0.87 | ALDH1A1 (0.36) | ALDH1A1TSHRPOLBMGAMGAA | |
| SCHEMBL9743398 | 0.83 | SMN1; SMN2 (0.32) | ALDH1A1TSHRANPEP | |
| SCHEMBL19204143 | 0.83 | ALDH1A1 (0.33) | ALDH1A1TSHRGAA | |
| SCHEMBL13540002 | 0.81 | — | — | |
| SCHEMBL1935146 | 0.81 | SLC1A3 (0.31) | GAA | |
| SCHEMBL7701394 | 0.77 | ANPEP (0.40) | ALDH1A1TSHRPOLBANPEP | |
| SCHEMBL15268831 | 0.77 | — | — | |
| SCHEMBL19858945 | 0.76 | MEN1 (0.39) | ALDH1A1TSHRPOLBMGAMGAA | |
| SCHEMBL4973862 | 0.76 | CA1 (0.35) | ALDH1A1TSHRCA1CA2ANPEP | |
| SCHEMBL16006410 | 0.76 | CA1 (0.35) | ALDH1A1CA1CA2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1450811-B1 | Compounds specific to adenosine A1 and A3 receptors and uses thereof | OSI PHARM INC (US) | 2009-10-21 | — | — | EP | disclosed |
| US-7598252-B2 | Compounds specific to adenosine A, receptors and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598252-B2 | Compounds specific to adenosine A, receptors and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090192177-A1 | 2-ARYL pyrrologpyrimidines for A1 and A3 receptors | OSI PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| EP-2050751-A1 | Compounds specific to adenosine A1 and A3 receptors and uses thereof | OSI Pharmaceuticals, Inc. (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20090082369-A1 | Pyrrolo[2,3d]pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. | 2009-03-26 | — | — | US | disclosed |
| US-7504407-B2 | Compounds specific to adenosine A1 and A3 receptors and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7429574-B2 | 4-heterocyclo-pyrrolo[2,3d] pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-20080070936-A1 | Compounds specific to adenosine A1 receptors and uses thereof | OSI PHARMACEUTICALS, INC. | 2008-03-20 | — | — | US | disclosed |
| US-20080070936-A1 | Compounds specific to adenosine A1 receptors and uses thereof | OSI PHARMACEUTICALS, INC. | 2008-03-20 | — | — | US | disclosed |
| US-7160890-B2 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-6680324-B2 | 4-AMINO-6-PHENYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2004-01-20 | — | — | US | disclosed |
| US-6680324-B2 | 4-AMINO-6-PHENYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2004-01-20 | — | — | US | disclosed |
| WO-2003048120-A2 | 2-ARYL PYRROLOGPYRIMIDINES FOR A1 AND A3 RECEPTORS | OSI PHARMACEUTICALS, INC. (US) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192177-A1 | 2-ARYL pyrrologpyrimidines for A1 and A3 receptors | ADORA3, ADORA1, ADORA2A | ALDH1A1 265/4885TSHR 197/4885CA1 4521/4885 |
| US-20090082369-A1 | Pyrrolo[2,3d]pyrimidine compositions and their use | ADORA3, ADORA2A, ADORA1 | ALDH1A1 1671/4885TSHR 246/4885CA1 4534/4885 |
| US-20080070936-A1 | Compounds specific to adenosine A1 receptors and uses thereof | ADORA1, ADORA2A, ADORA3 | ALDH1A1 255/4885TSHR 335/4885CA1 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.